Sinotau aims to become Hong Kong’s ‘first nuclear-medicine stock’
The company is China’s first to obtain approval for its innovative radiopharmaceuticals Key Takeaways: Sinotau has filed to list in Hong Kong, offering up two commercialized products and a net…
RELATED ARTICLES
-
Estenova aims to become a big name in medical aesthetics
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
- Neautus looks outward to boost its traditional medicine story
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
BRIEF: CATL targets $4 billion in Hong Kong IPO, poised to become year’s top listing
300750.SHE
